Cargando…

Clinical outcome in metastatic prostate cancer after primary radiotherapy

PURPOSE: To describe a local radio-oncological treatment for patients with prostate cancer that metastasized to either the lymph nodes or distant regions. METHODS AND MATERIALS: We included 133 patients with prostate cancer that displayed either distant metastases (DM) or lymph node metastases alone...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moll, Matthias, Herrmann, Harald, Zaharie, Alexandru, Goldner, Gregor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212832/ https://www.ncbi.nlm.nih.gov/pubmed/35953611 http://dx.doi.org/10.1007/s00066-022-01993-4

Ejemplares similares

Advancements in the radiooncological Treatment of High-risk Prostate Cancer: A Quarter Century of Achievements
por: Moll, Matthias, et al.
Publicado: (2022)

Biochemical control after adjuvant radiation therapy for prostate cancer: a unicentric, retrospective analysis
por: Zaharie, Alexandru-Teodor, et al.
Publicado: (2021)

Effects of Gold Fiducial Marker Implantation on Tumor Control and Toxicity in External Beam Radiotherapy of Prostate Cancer
por: Moll, Matthias, et al.
Publicado: (2023)

Treatment of low-risk prostate cancer: a retrospective study with 477 patients comparing external beam radiotherapy and I-125 seeds brachytherapy in terms of biochemical control and late side effects
por: Moll, Matthias, et al.
Publicado: (2020)

Comparison of EBRT and I-125 seed brachytherapy concerning outcome in intermediate-risk prostate cancer
por: Moll, Matthias, et al.
Publicado: (2021)

Comparative effectiveness of moderate hypofractionation with volumetric modulated arc therapy versus conventional 3D-radiotherapy after radical prostatectomy
por: Moll, Matthias, et al.
Publicado: (2022)

Comparison of treatment costs for primary localized prostate cancer in Austria and Vienna: an economic analysis
por: Moll, Matthias, et al.
Publicado: (2023)

Postoperative radiotherapy for prostate cancer: Morbidity of local-only or local-plus-pelvic radiotherapy
por: Waldstein, Cora, et al.
Publicado: (2017)

Long-Term Outcomes of Stereotactic Body Radiotherapy (SBRT) for Intraprostatic Relapse after Definitive Radiotherapy for Prostate Cancer: Patterns of Failure and Association between Volume of Irradiation and Late Toxicity
por: Miszczyk, Marcin, et al.
Publicado: (2023)

Ultra-Hypofractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer: Clinical Outcomes, Patterns of Recurrence, Feasibility of Definitive Salvage Treatment, and Competing Oncological Risk
por: Miszczyk, Marcin, et al.
Publicado: (2022)

Clinical outcomes of definitive whole pelvic radiotherapy for clinical lymph node metastatic prostate cancer
por: Tsuchida, Keisuke, et al.
Publicado: (2020)

Automated volumetric modulated arc therapy planning for whole pelvic prostate radiotherapy
por: Buschmann, Martin, et al.
Publicado: (2017)

Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer
por: Babst, Christa, et al.
Publicado: (2022)

Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer
por: Stefan A. Koerber, et al.
Publicado: (2020)

Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate
por: Roy, Soumyajit, et al.
Publicado: (2023)

Radiotherapy to the Primary Tumor: The First Step of a Tailored Therapy in Metastatic Prostate Cancer
por: Ferro, Matteo, et al.
Publicado: (2022)

RADIOTHERAPY OF PROSTATE CANCER: PRIMARY RADIOTHERAPY AND RADIOTHERAPY IN DISEASE RELAPSE
por: Antunac, Katarina
Publicado: (2019)

Prostate radiotherapy for metastatic hormone sensitive prostate cancer—myth or reality?
por: Onal, Cem
Publicado: (2019)

Treatment results of radiotherapy to both the prostate and metastatic sites in patients with bone metastatic prostate cancer
por: Inaba, Koji, et al.
Publicado: (2021)

Current Developments in Cellular Therapy for Castration Resistant Prostate Cancer: A Systematic Review of Clinical Studies
por: Steinbach, Christina, et al.
Publicado: (2022)

Long‐term clinical outcomes after 12‐fractionated carbon‐ion radiotherapy for localized prostate cancer
por: Sato, Hiraku, et al.
Publicado: (2021)

Pre-Treatment Hemoglobin Concentration and Absolute Monocyte Count as Independent Prognostic Factors for Survival in Localized or Locally Advanced Prostate Cancer Patients Undergoing Radiotherapy
por: Magrowski, Łukasz, et al.
Publicado: (2022)

Metastatic Spread in Prostate Cancer Patients Influencing Radiotherapy Response
por: Klusa, Daria, et al.
Publicado: (2021)

Interaction Between Modern Radiotherapy and Immunotherapy for Metastatic Prostate Cancer
por: Ollivier, Luc, et al.
Publicado: (2021)

Survival Outcomes and Prognostic Analysis Following Greater Cytoreductive Radiotherapy in Patients With Metastatic Prostate Cancer
por: Zhang, Zitong, et al.
Publicado: (2020)

Hypoxia Patterns in Primary and Metastatic Prostate Cancer Environments()
por: Bharti, Santosh Kumar, et al.
Publicado: (2019)

Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial
por: Ali, Adnan, et al.
Publicado: (2021)

Health-related quality of life of metastatic prostate cancer patients treated with prostate Radiotherapy
por: Ayoub, Heba Maged, et al.
Publicado: (2023)

Stereotactic Body Radiotherapy for Primary Prostate Cancer
por: Kothari, Gargi, et al.
Publicado: (2018)

Impact of androgen deprivation therapy on apparent diffusion coefficient and T2w MRI for histogram and texture analysis with respect to focal radiotherapy of prostate cancer
por: Daniel, M., et al.
Publicado: (2018)

Survival Outcomes After Radiotherapy for the Treatment of Synchronous Oligometastatic Prostate Cancer
por: Huynh, Linda My, et al.
Publicado: (2022)

WHO SHOULD RECEIVE RADIOTHERAPY IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER?
por: Bišof, Vesna
Publicado: (2019)

Outcomes after stereotactic body radiotherapy for lung tumors, with emphasis on comparison of primary lung cancer and metastatic lung tumors
por: Yamamoto, Takaya, et al.
Publicado: (2014)

Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy
por: Pinkawa, Michael, et al.
Publicado: (2012)

Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehensive review
por: Duijzentkunst, D. A. Smit, et al.
Publicado: (2016)

Hypofractionated radiotherapy for prostate cancer
por: Hegemann, Nina-Sophie, et al.
Publicado: (2014)

Prostate-specific antigen kinetics after stereotactic body radiotherapy as monotherapy or boost after whole pelvic radiotherapy for localized prostate cancer
por: Kim, Hun Jung, et al.
Publicado: (2015)

Low Hepatic Toxicity in Primary and Metastatic Liver Cancers after Stereotactic Ablative Radiotherapy Using 3 Fractions
por: Bae, Sun Hyun, et al.
Publicado: (2015)

Impact of clinical versus radiographic progression on clinical outcomes in metastatic castration-resistant prostate cancer
por: Rao, Arpit, et al.
Publicado: (2020)

Leptomeningeal Carcinomatosis of Metastatic Primary Prostate Cancer
por: Stenberg, Daniel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_12haae2o11gka9rijsrc2susjp